Please login to the form below

Not currently logged in
Email:
Password:

ceralifimod

This page shows the latest ceralifimod news and features for those working in and with pharma, biotech and healthcare.

Merck KGaA drops Ono-partnered multiple sclerosis drug

Merck KGaA drops Ono-partnered multiple sclerosis drug

The German pharma company said in a statement that ceralifimod (ONO-4641) "does not meet Merck's threshold for continued investment". . ... Ceralifimod is a sphingosine-1-phosphate (S1P) receptor-1 and -5 agonist and was licensed by Merck in 2011 for

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Access Consulting

OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. As value communications experts we specialise...

Latest intelligence

2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...
The 10-year Web Challenge
Understanding your users’ needs is more critical online today than ever. A site should mould itself around these insights, deliver those needs quickly, efficiently and with plenty of white space....
Downloadable Pack: Understanding Multiple Sclerosis
Inside this downloadable pack, you’ll find a wealth of exclusive information on the way multiple sclerosis is commonly treated today. As well as areas of continuous improvement for the industry....

Infographics